Home / Market News / $HALO

$HALO news and market catalysts

The 20 most recent market catalysts affecting $HALO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

20 catalysts 3 high impact 12 bullish 2 bearish Biotechnology
Nov 17, 2026 Corporate Catalyst Neutral Impact 55
Halozyme Therapeutics Insider Sells Shares Worth Over $6 Million
A Halozyme Therapeutics insider sold shares valued at over $6 million, as reported in a recent SEC filing. This event is a standard disclosure for corporate insiders and does not i…
Nov 11, 2026 Corporate Catalyst Bearish Impact 55
Morgan Stanley Downgrades Halozyme Therapeutics to Equalweight
Morgan Stanley downgraded Halozyme Therapeutics from Overweight to Equalweight, signaling a reduced level of conviction in the stock's outperformance. Despite the downgrade, the pr…
Nov 11, 2026 Corporate Catalyst Bearish Impact 65
Morgan Stanley Downgrades Halozyme Therapeutics to Equalweight From Overweight
Morgan Stanley, a prominent investment bank, downgraded Halozyme Therapeutics from an 'Overweight' to an 'Equalweight' rating, accompanied by a $109 price target. This action signa…
Nov 6, 2026 Corporate Catalyst Neutral Impact 65
Halozyme Projects Minimal Impact from Medicare Drug Price Negotiation Program
Halozyme Therapeutics conducted an internal assessment of the recently finalized Medicare Drug Price Negotiation Program. The company's conclusion that it expects zero to minimal i…
Nov 6, 2026 Corporate Catalyst Bullish Impact 75
FDA Grants Accelerated Approval to RYBREVANT FASPRO™ for Head and Neck Squamous Cell Carcinoma
The FDA has granted accelerated approval to RYBREVANT FASPRO™ for head and neck squamous cell carcinoma. This is significant because the therapy incorporates Halozyme's proprietary…
Nov 5, 2026 Corporate Catalyst Bullish Impact 92
Halozyme Therapeutics Reports Q3 2026 Financial Results and Raises Full-Year Guidance
Halozyme Therapeutics announced impressive Q3 2026 financial results, with revenue up 39.2% year-over-year and royalty revenue growing by 44%. This strong performance led managemen…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130
TD Cowen analyst Brendan Smith maintained a 'Buy' rating on Halozyme Therapeutics and raised the price target from $105 to $130. This indicates a strengthened positive outlook from…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130
HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on Halozyme Therapeutics (HALO) and raised the price target from $115 to $130. This indicates a strengt…
Oct 6, 2026 Corporate Catalyst Bullish Impact 65
Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets
Halozyme Therapeutics has expanded its existing collaboration with argenx, adding two new exclusive targets for its ENHANZE drug delivery technology. This is significant because it…
Sep 18, 2026 Corporate Catalyst Bullish Impact 75
Reported Earlier, Halozyme Therapeutics Prices Upsized $1.3B Offering Of 1.50% Convertible Senior Notes Due 2033
This headline signifies a significant financing event for Halozyme Therapeutics. The upsized offering of convertible senior notes provides a substantial capital injection, which ca…
Sep 16, 2026 Corporate Catalyst Neutral Impact 65
Halozyme Therapeutics Announces Proposed $1.05B Convertible Senior Notes Offering Due 2033
Halozyme Therapeutics is seeking to raise $1.05 billion through the issuance of convertible senior notes, with an option for an additional $150 million. This financing strategy all…
Aug 25, 2026 Market Technicals Neutral Impact 55
Watching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Sells Stock
This headline primarily reflects a technical signal rather than a fundamental change in Halozyme Therapeutics' business. The 'Investor Business Daily SwingTrader' is a recognized e…
Aug 17, 2026 Corporate Catalyst Neutral Impact 55
Watching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Buys Stock
The headline indicates that Investor's Business Daily's SwingTrader, a publication known for technical analysis and short-term trading signals, has bought stock in Halozyme Therape…
Aug 8, 2026 Corporate Catalyst Bullish Impact 65
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110
Leerink Partners' upgrade of Halozyme Therapeutics from Market Perform to Outperform, coupled with a significant price target increase from $83 to $110, indicates a more bullish ou…
Aug 7, 2026 Corporate Catalyst Bullish Impact 60
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105
TD Cowen analyst Brendan Smith has maintained a 'Buy' rating on Halozyme Therapeutics and raised the price target from $96 to $105. This upgrade in price target indicates increased…
Aug 7, 2026 Corporate Catalyst Bullish Impact 85
Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates. HC Wainwright & Co raised its price target on the stock from $95 to $115.
This headline indicates a strong positive catalyst for Halozyme Therapeutics. Better-than-expected earnings and, more importantly, raised long-term guidance (FY26) suggest fundamen…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $115
HC Wainwright & Co. analyst Mitchell S. Kapoor has maintained a 'Buy' rating on Halozyme Therapeutics and raised the price target from $95 to $115. This action signals increased co…
Aug 6, 2026 Corporate Catalyst Bullish Impact 95
Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate
Halozyme Therapeutics reported Q2 adjusted EPS of $2.28, significantly beating the $1.84 estimate by 23.91%, and sales of $480.999 million, surpassing the $407.493 million estimate…
Jul 21, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reaffirmed a 'Buy' rating and a $95 price target for Halozyme Therapeutics. This action signals that the analyst's investment the…
Jul 20, 2026 Corporate Catalyst Bullish Impact 65
Halozyme Therapeutics Signs Agreement With Incyte To Mull Additional Subcutaneous Formulations Of INCA033989 Mutant Calreticulin-Targeted Monoclonal Antibody
Halozyme Therapeutics announced a collaboration with Incyte to improve the subcutaneous delivery of Incyte's INCA033989, a promising cancer drug. This is a positive development for…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.